In these participants, glibenclamide (0.3-0.6 mg/day for 14-18 days) raised circulating glucagon during hypoglycaemia by 125-150%; this correlated with reduced glucose infusion requirements, reflecting stimulation of endogenous glucose production. This evidence concerns the gene GCG and Hypoglycemia.